Abstract

Our objective is to characterize the effects of ligand-induced ErbB4 signaling on the behavior of human breast, prostate, and pancreatic tumor cell lines. We have four specific aims: (1) Establish tumor cell model systems and determine the effects of ligand-induced ErbB4 signaling. (2) Determine the mechanisms by which ErbB4 is coupled to downstream biological effects. (3) Assess the role of ErbB receptor heterodimerization in coupling ErbB4 ligands to downstream biological effects. (4) Determine the structure of the ErbB4 extracellular domain bound to various NRG isoforms and mutants. A hypothesis that will be emphasized throughout this effort is that different Neuregulin isoforms differentially stimulate ErbB4 signaling and coupling to biological responses. The results of these experiments will shed new insight into the pathogenesis of breast, prostate, and pancreatic cancers. Moreover, they will suggest potential strategies for the treatment of these diseases.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA114209-06
Application #
8371354
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Woodhouse, Elizabeth
Project Start
2006-08-01
Project End
2012-07-31
Budget Start
2011-12-01
Budget End
2012-07-31
Support Year
6
Fiscal Year
2010
Total Cost
$57,264
Indirect Cost

  Institution

Name
Auburn University at Auburn
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
066470972
City
Auburn University
State
AL
Country
United States
Zip Code
36849

  Publications

Riese 2nd, David J; Cullum, Richard L (2014) Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 28:49-56
Gallo, Richard M; Bryant, Ianthe N; Mill, Christopher P et al. (2013) Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. J Cancer Res Ther Oncol 1:10
Nickerson, Nicole K; Mill, Christopher P; Wu, Hsin-Jung et al. (2013) Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res 20:303-17
Wilson, Kristy J; Mill, Christopher P; Gallo, Richard M et al. (2012) The Q43L mutant of neuregulin 2? is a pan-ErbB receptor antagonist. Biochem J 443:133-44
Foley, John; Nickerson, Nicole; Riese 2nd, David J et al. (2012) At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology 100:109-29
Wilson, Kristy J; Mill, Christopher; Lambert, Sydney et al. (2012) EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30:107-16
Riese 2nd, David J (2011) Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert Opin Drug Discov 6:185-193
Zordan, Michael D; Mill, Christopher P; Riese 2nd, David J et al. (2011) A high throughput, interactive imaging, bright-field wound healing assay. Cytometry A 79:227-32
Mill, Christopher P; Gettinger, Kathleen L; Riese 2nd, David J (2011) Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317:392-404
Foley, John; Nickerson, Nicole K; Nam, Seungyoon et al. (2010) EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 21:951-60

Showing the most recent 10 out of 21 publications